Beijing Diagreat Biotechnologies Co., Ltd. (hereinafter referred to as 'Diagreat') was established in 2013, headquartered in Beijing Economic and technological Development Zone.  

Diagreat has a mature research and production platform for key raw materials upstream in the field of in vitro diagnosis and life science, which includes small molecule directional coupling technology, antibody research and production, protein engineering technology, enzyme molecular engineering technology, nucleic acid synthesis and modification, primer probe synthesis, gene synthesis and sequencing, etc. 

Diagreat has a series of in vitro diagnostic products domestic registration certificate, the core products include POCT series, Clinical Chemistry series, Chemiluminescence series, including Therapeutic Drug Monitoring (TDM) series of characteristic products. Series of products have also passed the CE certification, Italy, Mexico and Ecuador and other countries certification, and already sold to more than 60 countries and regions around the world. 

Diagreat has dozens of patents for invention, we successively won the honorary titles of 'National High-tech Enterprise', 'Zhongguancun High-tech Enterprise', 'Beijing 'Specialization, Refinement, Differentiation, Innovation' of small and medium-sized Enterprises', 'Beijing Golden seed Enterprise', 'Yizhuang Deloitte Top 20 growth' and other honorary titles. Diagreat has won the First Prize for Scientific and Technological progress in Beijing, undertaken one national key scientific and technological research and development project, and has successively completed a number of key scientific and technological research and development projects in Beijing, as well as a number of regional science and technology projects.